UBS upgrades Altria stock rating to Neutral on improved outlook

UBS upgraded Altria (MO) to Neutral with a $59 price target, citing increased enforcement against illicit vape products, which is expected to improve the company's cigarette volume trends and positively revise its 2026 EPS outlook. This favorable development for Altria, which has a robust 7% dividend yield, is further underscored by S&P Global Ratings' upgrade of its credit to 'BBB+' from 'BBB', reflecting strong credit metrics, profitability, and pricing power despite ongoing industry challenges.

Analysis

Altria (MO) has received a significant vote of confidence from UBS, which upgraded the stock to Neutral from Sell and raised its price target to $59.00 from $47.00. The core catalyst for this revision is mounting evidence of a regulatory crackdown on illicit vape products, a headwind that has suppressed Altria's performance for the past five years. This enforcement is manifesting in tangible supply chain disruptions, evidenced by a 40% year-over-year decline in vapor product exports from China to the U.S. in May and production halts by major illicit brand manufacturers. UBS quantifies the potential impact as a 100-basis-point improvement in the rate of industry cigarette volume decline, forecasting a slowdown to -8.0% YoY. Consequently, UBS has revised its outlook, no longer projecting an earnings per share decline for Altria in 2026. This improved operational outlook is buttressed by strong underlying financial health, as validated by S&P Global Ratings' recent credit rating upgrade to 'BBB+' with a stable outlook, citing Altria's pricing power and strong profitability. The company's robust 7% dividend yield, supported by 15 consecutive years of increases, remains a key pillar of its investment thesis, although challenges such as the patent-related removal of its NJOY ACE e-vapor product persist.

Key Decisions for Investors

• Investors should re-evaluate Altria's prospects in light of the regulatory crackdown on illicit vapes, as this could serve as a significant catalyst to improve cigarette volume trends and support a higher valuation.
• For income-focused portfolios, the 7% dividend yield, now reinforced by an S&P credit rating upgrade to 'BBB+', appears more secure and presents a compelling case for holding or accumulating a position.
• It is crucial to monitor the effectiveness and durability of customs enforcement against illegal vapes and any developments in the patent dispute affecting the NJOY ACE product, as these factors represent key variables in the company's future performance.